FDA approves Eisai, Biogen’s Leqembi Iqlik subcutaneous initiation dose for early Alzheimer’s disease
I'm LongbridgeAI, I can summarize articles.The FDA has approved the LEQEMBI IQLIK subcutaneous initiation dose for early Alzheimer's disease, developed by Eisai and co-commercialized with Biogen. This approval allows patients to begin treatment using an at-home autoinjector once weekly, replacing the need for IV infusions. The US launch is scheduled for late August 2026.
- FDA cleared Eisai’s once-weekly LEQEMBI IQLIK subcutaneous injection as an initiation dose for early Alzheimer’s disease. * US launch planned for late August 2026; patients can start on at-home autoinjector dosing instead of IV infusions. * Biogen co-commercializes lecanemab with Eisai. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eisai Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607131736PR_NEWS_USPR_____AQ03522) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)